Section of Infectious Diseases, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
Vaccine. 2013 Aug 28;31 Suppl 4:D3-6. doi: 10.1016/j.vaccine.2013.02.030.
The progressive unfolding, over four decades, of an understanding of group B Streptococcus (GBS) and its global disease burden support the rationale for maternal immunization as a key strategy to prevent GBS perinatal infections. This review highlights, in historical context, the recognition of GBS as a human pathogen, definition of epidemiologic features of disease, pathogenesis, outcomes, impact of intrapartum antibiotic prophylaxis, development of glycoconjugate vaccines and appreciation of the global scope of GBS perinatal disease. These cumulative advances in the GBS field coupled with an increasing acceptance of immunization during pregnancy suggest the timing is optimal for introduction of a glycoconjugate GBS vaccine for use in pregnant women.
四十年来，对 B 组链球菌（GBS）的认识及其在全球的疾病负担逐渐明朗，这为孕产妇免疫接种作为预防 GBS 围产期感染的关键策略提供了依据。本综述从历史背景出发，重点介绍了 GBS 作为一种人类病原体的认识、疾病的流行病学特征、发病机制、结局、产时抗生素预防的影响、糖结合疫苗的发展以及对 GBS 围产期疾病全球范围的认识。GBS 领域的这些累积进展，加上越来越多的人接受孕期免疫接种，表明现在是为孕妇引入 GBS 糖结合疫苗的最佳时机。
